ClinicalTrials.gg

Program

STR-P004

Also written as “STR-P004 dose group”.

Its studies are mostly in Autoimmune Diseases · Lymphoma, Non-Hodgkin, led by Starna Therapeutics.

Furthest: early phase 1, since May 19, 20253 company-led studies, 3 open or runningNext primary completion: Feb 1, 2027

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Starna Therapeutics33 open or runningearly phase 1since May 19, 2025May 19, 2025Feb 1, 2027NCT07363954

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2025First study: early phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT07003178 · 30 planned · China
  2. Nov 17, 2025No phase study in Acute Lymphobkastic LeukemiaNCT07245251 · 11 planned
  3. Jan 15, 2026No phase study in Autoimmune DiseasesNCT07363954 · 9 planned

Ahead

  1. Nov 2, 2026Primary completion: no phase study in Acute Lymphobkastic LeukemiaNCT07245251
  2. Feb 1, 2027Primary completion: no phase study in Autoimmune DiseasesNCT07363954

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07363954Autoimmune Diseases–Not yet recruitingFeb 1, 20279
NCT07245251Acute Lymphobkastic Leukemia–Not yet recruitingNov 2, 202611
NCT07003178Lymphoma, Non-Hodgkin · ChinaEarly 1Not yet recruitingApr 202630

How it is read

Names in the registry

  • “STR-P004”, 2 entries
  • “STR-P004 dose group”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.